(Q28323119)

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

6 June 2022

3

D B Calne

0 references

author name string

L. E. Claveria

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235013

6 June 2022

P. F. Teychenne

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235013

6 June 2022

L. Haskayne

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235013

6 June 2022

A. Petrie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235013

6 June 2022

C. A. Pallis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235013

6 June 2022

I. C. Lodge-Patch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A235013

full work available at URL

6 June 2022

language of work or name

English

0 references

publication date

April 1975

0 references

https://api.elsevier.com/content/article/PII:0022510X75901653?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

https://api.elsevier.com/content/article/PII:0022510X75901653?httpAccept=text/plain

6 June 2022

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Journal of the Neurological Sciences

6 June 2022

published in

0 references

volume

24

0 references

issue

4

0 references

page(s)

393-401

0 references

cites work

Receptor activity and turnover of dopamine and noradrenaline after neuroleptics

1

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Risks vs. benefits of antipsychotic drugs.

6 June 2022

2

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Neuropathological investigation of 28 brains from patients with dyskinesia

6 June 2022

4

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

6 June 2022

Persistent Dyskinesia

5

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes

6 June 2022

6

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Persistent Phenothiazine Dyskinesia Treated with Tetrabenazine

6 June 2022

7

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.

6 June 2022

9

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Theoretical implications of the use of L-dopa in parkinsonism. A review

6 June 2022

11

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia

6 June 2022

12

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Pathophysiology of drug-induced dyskinesias

6 June 2022

13

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Treatment of Persistent Phenothiazine-induced Oral Dyskinesia

6 June 2022

15

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

Thiopropazate Hydrochloride in Persistent Dyskinesia

6 June 2022

16

1 reference

https://api.crossref.org/works/10.1016/0022-510X(75)90165-3

6 June 2022

Identifiers

0 references